Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for OTC:ARDM
4.50
+0.05 (1.12%)
Jun 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.40 - 4.51
52 week 2.60 - 7.90
Open 4.50
Vol / Avg. 0.00/7,121.00
Mkt cap 67.25M
P/E     -
Div/yield     -
EPS -1.64
Shares 14.94M
Beta 0.97
Inst. own 45%
Aug 11, 2016
Q2 2016 Aradigm Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 10, 2016
Q1 2016 Aradigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -134766.70% -73.45%
Operating margin -134833.30% -73.21%
EBITD margin - -72.30%
Return on average assets -103.83% -38.42%
Return on average equity -168.92% -55.31%
Employees 16 -
CDP Score - -

Address

3929 Point Eden Way
HAYWARD, CA 94545-3720
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Officers and directors

Virgil D. Thompson J.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Robert A. Reed Ph.D. Vice President - Regulatory (CMC) and Quality
Bio & Compensation  - Reuters
Juergen Froehlich M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
David Bell Director
Age: 60
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters